Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

108.67 +1.87 (+1.75%)
Official Closing Price Updated: 4:10 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
65 66 Next >
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Anti-obesity therapeutics are all the rage and for good reason. Investors seeking to profit should consider these weight loss stocks. 
Via InvestorPlace
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth. 
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals. 
Via InvestorPlace
Smart Money Is Betting Big In NVO Options
Via Benzinga
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
FDA reports hospitalizations due to overdoses from compounded semaglutide products. Patients and health care providers miscalculate doses, leading to serious adverse events. The FDA advises proper... 
Via Benzinga
Exposures Product Safety
Novo Nordisk Unusual Options Activity For July 26
Via Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Liraglutide shows promise in slowing cognitive decline in Alzheimer's patients, reducing brain volume loss and offering neuroprotective benefits, according to a Phase 2b clinical trial presented at... 
Via Benzinga
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
A study finds smokers with diabetes on Ozempic have fewer smoking-related medical interactions and interventions compared to those on other diabetes drugs. Research suggests potential for semaglutide... 
Via Benzinga
NYSE:NVO stands out as a growth opportunity that won't break the bank.
Investors should take note ofNOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced. 
Via Chartmill
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. 
Via The Motley Fool
3 Overlooked Stocks Poised for a Breakout Very Soon
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio. 
Via InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
There's reason to believe that one of these two players will eventually win. 
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Roche's latest breakthrough could be a game changer, but it's still too early to say. 
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Should you get in on this stock now? 
Via The Motley Fool
This Could Send Ozempic's Sales Potential to a Whole Other Level
Ozempic could pile up a lot more indications in the years ahead. 
Via The Motley Fool
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
The company should maintain its lead in this growing area. 
Via The Motley Fool
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Small caps continued to lead, while the Nasdaq broke below key levels. 
Via Investor's Business Daily
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category. 
Via The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX). 
Via Benzinga
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Viking Therapeutics Inc (NASDAQ:VKTX) shares are rising Thursday after the biotech company announced plans to advance its experimental weight loss drug to late-stage trials. 
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug. 
Via Investor's Business Daily
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
Beware, Wegovy -- Pfizer Is Working on a Competitor
Pfizer wants to maintain its recent run of key approvals. 
Via The Motley Fool
3 Fabulous Growth Stocks to Buy and Hold Forever
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available. 
Via InvestorPlace
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
The NHS has prescribed Wegovy far less often than expected due to a shortage of weight management clinics, highlighting significant challenges in meeting growing demand for the weight-loss drug. 
Via Benzinga
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. 
Via Benzinga
3 Stocks to Buy if There Is No Interest Rate Cut This Year
Here are three stocks to buy and hold for steady gains if the Federal Reserve decides against an interest rate cut in 2024. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.